Erste Asset Management Gmb H Ascendis Pharma A/S Transaction History

Erste Asset Management Gmb H

$8.15 Trillion
Q4 2024

A detailed history of Erste Asset Management Gmb H transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Erste Asset Management Gmb H holds 20,300 shares of ASND stock, worth $3.16 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

20,300

Previous 20,300 -0.0%

Holding current value

$3.16 Million

Previous $2.94 Billion 4.92%

% of portfolio

0.03%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $2.29 Million - $3.11 Million	20,300 New	20,300 $2.94 Billion
Q1 2023 Nov 26, 2024	BUY	$104.9 - $126.78 $776,260 - $938,172	7,400 Added 66.67%	18,500 $2.01 Billion
Q4 2022 Nov 26, 2024	BUY	$99.42 - $131.97 $735,708 - $976,578	7,400 Added 66.67%	18,500 $2.24 Billion
Q3 2022 Nov 26, 2024	SELL	$84.03 - $110.23 $773,076 - $1.01 Million	-9,200 Reduced 45.32%	11,100 $1.14 Billion
Q2 2022 Nov 26, 2024	SELL	$78.08 - $117.61 $718,336 - $1.08 Million	-9,200 Reduced 45.32%	11,100 $1.05 Billion
Q1 2022 Nov 22, 2024	SELL	$102.18 - $135.75 $296,322 - $393,675	-2,900 Reduced 20.71%	11,100 $1.29 Billion
Q4 2021 Nov 22, 2024	SELL	$127.1 - $169.66 $800,730 - $1.07 Million	-6,300 Reduced 31.03%	14,000 $1.87 Billion
Q4 2020 Nov 22, 2024	BUY	$151.2 - $182.76 $2.12 Million - $2.56 Million	14,000 New	14,000 $2.33 Billion
Q3 2020 Nov 22, 2024	SELL	$134.29 - $154.32 $2.73 Million - $3.13 Million	-20,300 Closed	0 $0
Q2 2020 Nov 22, 2024	BUY	$110.87 - $156.01 $0 - $0	0 New	0 $0
Q1 2020 Nov 22, 2024	SELL	$97.01 - $145.11 $1.97 Million - $2.95 Million	-20,300 Closed	0 $0

Others Institutions Holding ASND

# of Institutions

235

Shares Held

59.5M

Call Options Held

80.3K

Put Options Held

216K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.7B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Account

Erste Asset Management Gmb H Ascendis Pharma A/S Transaction History